Characterization of topoisomerase IIα gene amplification and deletion in breast cancer

Topoisomerase IIα (TOP2A) is a key enzyme in DNA replication and a molecular target for many important anticancer drugs. TOP2A is amplified or deleted together with amplification of the closely located ERBB2/HER‐2/neu oncogene in breast cancer. We characterized the copy number aberrations of TOP2A and ERBB2 in 136 primary breast tumors by FISH. Among the 70 primary tumors with ERBB2 amplification, amplification of TOP2A was found in 29 (41%); 30 tumors (43%) showed a physical deletion of TOP2A; and the copy number for TOP2A was not altered in 11 tumors with ERBB2 amplification (16%). No TOP2A gene aberrations were identified in 65 primary tumors without ERBB2 amplification. Fiber FISH revealed that simultaneously amplified ERBB2 and TOP2A were not present in the same amplicon, because repetitive tandem repeat‐like signals of ERBB2 and TOP2A were in separate DNA fibers. The deletion of TOP2A (seen in the MDA‐361 cell line and in 31 primary tumors) was interstitial, spanning less than two megabases of DNA. Mean copy numbers of TOP2A (2.4 ± 0.6 for TOP2A vs. 4.9 ± 1.1 for chromosome 17 centromere) suggest that the deletion of TOP2A occurs before polyploidization of the genome. Eight primary tumors with high‐level ERBB2 amplification showed a new type of intratumoral heterogeneity; two different cell clones with either high‐level amplification or deletion of TOP2A were found adjacent to each other in the same tumor. These results indicate that amplification of the ERBB2 oncogene is followed by complex secondary genetic aberrations, which lead to amplification or deletion of the TOP2A gene in a majority of tumors. Genes Chromosomes Cancer 26:142–150, 1999. © 1999 Wiley‐Liss, Inc.

[1]  L. Peltonen,et al.  Mapping ESTs by fiber-FISH. , 1999, Genome research.

[2]  S. Gasser,et al.  Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide. , 1996, British Journal of Cancer.

[3]  S. Withoff,et al.  Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. , 1996, British Journal of Cancer.

[4]  J. Kononen,et al.  Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. , 1996, The American journal of pathology.

[5]  E. Mallon,et al.  Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ , 1995, International journal of cancer.

[6]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[7]  A. Harris,et al.  Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. , 1993, Oncogene.

[8]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[9]  F. Toledo,et al.  Expression of Fragile Sites Triggers Intrachromosomal Mammalian Gene Amplification and Sets Boundaries to Early Amplicons , 1997, Cell.

[10]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N E Morton,et al.  Parameters of the human genome. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Wishart,et al.  Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 , 1993 .

[13]  A. Raap,et al.  Advances in fluorescence in situ hybridization. , 1998, Mutation research.

[14]  C. Robson,et al.  Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. , 1988, The Journal of biological chemistry.

[15]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[16]  J. Varley,et al.  Identification of genetic changes associated with drug resistance by reverse in situ hybridization. , 1997, British Journal of Cancer.

[17]  G. Dunnington,et al.  MDR1 gene expression in primary and advanced breast cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[18]  P. Basset,et al.  Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. , 1995, Genomics.

[19]  P. Meltzer,et al.  Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. , 1996, Cancer research.

[20]  M. Fernö,et al.  Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. , 1992, Cytometry.

[21]  R. Gelman,et al.  Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Coquelle,et al.  Interstitial deletions and intrachromosomal amplification initiated from a double‐strand break targeted to a mammalian chromosome , 1998, The EMBO journal.

[23]  O. Kallioniemi,et al.  Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17 , 1998, Cytogenetic and Genome Research.

[24]  C. Morelli,et al.  Characterization of a 4-Mb region at chromosome 6q21 harboring a replicative senescence gene. , 1997, Cancer research.

[25]  S. Knuutila,et al.  Concomitant gastrin and ERBB2 gene amplifications at 17q12–q21 in the intestinal type of gastric cancer , 1999, Genes, chromosomes & cancer.

[26]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[27]  S. Bautista,et al.  CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei , 1998, Genes, chromosomes & cancer.

[28]  E. Kleinerman,et al.  Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. , 1996, The Biochemical journal.

[29]  I. Roninson,et al.  Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L Peltonen,et al.  Visual mapping by fiber-FISH. , 1995, Genomics.

[31]  W. Kuo,et al.  Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. , 1994, Cancer research.

[32]  M. Jasin,et al.  Homology-directed repair is a major double-strand break repair pathway in mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  N. Osheroff,et al.  Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*) , 1995, The Journal of Biological Chemistry.

[34]  M. Fernö,et al.  Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. , 1998, The American journal of pathology.

[35]  M. J. van de Vijver,et al.  p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. Kuo,et al.  A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. , 1995, Genomics.

[37]  G. Casey,et al.  Four regions of allelic imbalance on 17q12‐qter associated with high‐grade breast tumors , 1997, Genes, chromosomes & cancer.

[38]  S. Withoff,et al.  Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. , 1996, British Journal of Cancer.

[39]  A. Schneeweiss,et al.  Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer , 1999, British Journal of Cancer.

[40]  M. Höglund,et al.  FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q , 1998, Genes, chromosomes & cancer.

[41]  J. Isola,et al.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. , 1998, British Journal of Cancer.

[42]  M. Fernö,et al.  ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.

[43]  O. Kallioniemi,et al.  Increased copy number at 17q22‐q24 by CGH in breast cancer is due to high‐level amplification of two separate regions , 1997, Genes, chromosomes & cancer.

[44]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[45]  E. Kleinerman,et al.  Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. , 1996, British Journal of Cancer.